GNI Group (2160) Fundamentals 2026 — Revenue Analysis | SniperIQ
GNI Group (2160) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥139.3B, trading at ¥2499.00 on the JPX. This SniperIQ fundamentals page covers GNI Group's valuation, profitability (net margin -22.2%), revenue (¥26.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GNI Group's market cap?
GNI Group (2160) has a market capitalization of approximately ¥139.3B, trading at ¥2499.00 on the JPX. Market cap moves with the live share price.
What is GNI Group's P/E ratio?
GNI Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GNI Group?
GNI Group runs a net profit margin of -22.2%, a gross margin of 73.6%, and an operating margin of -15.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GNI Group generate?
GNI Group reported revenue of ¥26.8B for fiscal year 2025, with net income of -¥4.4B and earnings per share (EPS) of -84.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GNI Group pay a dividend?
GNI Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is GNI Group financially healthy?
GNI Group carries a debt-to-equity ratio of 0.10x and a current ratio of 4.08x, with a market beta of 1.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GNI Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GNI Group (2160) the key facts are: market cap ¥139.3B, revenue ¥26.8B, 52-week range 2112-3740. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GNI Group's full fundamentals live
Get GNI Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.